JAGXNCMHealthcare·Biotechnology#559 in industry

Jaguar Health, Inc.

Reports in 17d· 2026-05-14

-56.5% · 90d

$0.31

-0.08 (-21.08%)

News

(1)

April 2026

Apr 7, 20262 weeks ago8-KHealthcare

Jaguar Health, Inc. — 8-K Filing

JAGXJaguar Health, Inc.

# 🧾 What This Document Is This is an 8-K filing, which is like a company's "urgent bulletin" to the SEC and investors. It reports major news that happens between quarterly earnings reports. In this case, Jaguar Health is sharing two big things: its financial results for the last quarter of 2025 and

Read summaryView on SEC EDGAR

Key Data

Market Cap$4.0M

Open$0.38

Prev Close$0.39

Day Range$0.31 – $0.38

52W Range$0.31 – $13.25

Volume1,061,607

P/E (TTM)—

EPS$-22.97

Dividend Yield—

Beta0.29

Revenue Growth-7.80%

Price Target$7.50(+2346.2%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy1 analysts

Buy 1Hold 0Sell 0

About

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Healthcare · Biotechnology

47 employees

jaguar.health